Top Biotech Stocks to Watch Now: Momentum, Milestones & Market Breakouts

July 28, 2025

DENVER, Colo., Jul 28, 2025 (247marketnews.com)- The biotech sector is buzzing with momentum as companies push into late-stage clinical trials, sign landmark agreements, and commercialize novel platforms.

Kraig Biocraft Laboratories (OTCQB:KBLB) is pioneering next-generation biomaterials using recombinant spider silk, a unique niche in biotechnology. Kraig just signed a multi-year agreement with a government agency in Southeast Asia to accelerate its production.

“This milestone reflects many years of work by our senior management and on-the-ground team,” said COO Jon Rice. “With the support of this agreement, we are now positioned to move more quickly and efficiently toward large-scale commercialization.”

KBLB expects to begin operations in early August. This marks a pivotal moment for its commercial expansion strategy.

Adial Pharmaceuticals (NASDAQ:ADIL) is advancing the development of AD04, its genetically targeted therapeutic for alcohol use disorder (AUD), which has shown promise in patients with a specific serotonin transporter genotype.

CervoMed (NASDAQ:CERV) is focused on developing therapies for degenerative brain diseases and is gaining traction after the FDA granted Fast Track Designation for its lead candidate, neflamapimod, in treating dementia with Lewy bodies. The company’s latest clinical update reaffirmed patient tolerability and early efficacy signals.

Full Alliance Group’s (OTC:FAGI) entry into telehealth and men’s wellness is worth watching. Today, it reported that its Q2 2025 Revenue estimate surged by 47% YoY and is expected to top $1 million in Q3, fueled by DTC subscriptions, testosterone booster launches, and contract manufacturing. Their hypochlorous acid (HOCl) division recently secured agricultural contracts, including a pig sanitization product line. This cross-sector expansion shows how health-focused microcaps can gain from biotech-adjacent markets and turned Full Alliance into one of the top performing stocks of July 2025.

aTyr Pharma (NASDAQ:LIFE) is pioneering novel therapeutics derived from extracellular tRNA synthetase biology. The company recently initiated a Phase 3 trial of efzofitimod for pulmonary sarcoidosis, following encouraging Phase 2b data. As one of the few public companies focused on this orphan lung disease, aTyr is positioned at the forefront of niche immunological treatment strategies. Investors are watching for mid-stage trial updates and partnership developments in Q3.

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage radiotherapeutics company, developing targeted radiation treatments for rare and difficult-to-treat cancers. The company is actively enrolling patients in its ReSPECT-GBM trial, a precision radiotherapy program for glioblastoma. The company is also expanding into other CNS indications. Plus recently received orphan drug designation and is set to release additional data before year-end.

INmune Bio (NASDAQ:INMB) is focused on neuroinflammation and cancer immunotherapy, and developing XPro1595, which has demonstrated ability to reduce neuroinflammation markers in Alzheimer’s Disease and treatment-resistant depression.

Vor Biopharma (NASDAQ:VOR) is advancing engineered hematopoietic stem cell (eHSC) therapies, aimed at transforming the treatment of blood cancers. Their VOR33 + VCAR33 combo is under evaluation in AML patients. Recent updates from ongoing trials underscore tolerability and early signs of efficacy.

Entera Bio (NASDAQ:ENTX) is developing oral formulations of large molecules, like PTH for osteoporosis and hGH for growth disorders. This year, the company is expected to release clinical data on its oral parathyroid hormone candidate, which could position it as a disruptor to injectable biologics.

AIM ImmunoTech (NYSE:AIM) is advancing Ampligen, a broad-spectrum immune-modulating RNA agent, for indications including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and various cancers. Recent progress includes updates in pancreatic cancer combination trials and expanded compassionate use protocols.

Please go to https://247marketnews.com/kblb-disclosure/ for additional 247marketnews.com KBLB disclosure. 24/7 Market News is paid to publish press releases and editorials for FAGI.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, ADIL, CERV, LIFE, PSTV, AIM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.